These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35033008)

  • 1. THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy.
    Chiloiro G; Cusumano D; Boldrini L; Romano A; Placidi L; Nardini M; Meldolesi E; Barbaro B; Coco C; Crucitti A; Persiani R; Petruzziello L; Ricci R; Salvatore L; Sofo L; Alfieri S; Manfredi R; Valentini V; Gambacorta MA
    BMC Cancer; 2022 Jan; 22(1):67. PubMed ID: 35033008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. THeragnostic utilities for neoplastic DisEases of the rectum by MRI guided radiotherapy (THUNDER 2) phase II trial: interim safety analysis.
    Chiloiro G; Romano A; Cusumano D; Boldrini L; Panza G; Placidi L; Meldolesi E; Nardini M; Meffe G; Nicolini G; Votta C; Indovina L; Gambacorta MA
    Radiat Oncol; 2023 Oct; 18(1):163. PubMed ID: 37803322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 5. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
    Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
    BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC).
    Crimì F; Capelli G; Spolverato G; Bao QR; Florio A; Milite Rossi S; Cecchin D; Albertoni L; Campi C; Pucciarelli S; Stramare R
    Radiol Med; 2020 Dec; 125(12):1216-1224. PubMed ID: 32410063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study.
    Voogt ELK; Schaap DP; van den Berg K; Nieuwenhuijzen GAP; Bloemen JG; Creemers GJ; Willems J; Cnossen JS; Peulen HMU; Nederend J; van Lijnschoten G; Burger JWA; Rutten HJT
    Eur J Surg Oncol; 2021 Sep; 47(9):2429-2435. PubMed ID: 34030921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.
    Hoendervangers S; Couwenberg AM; Intven MPW; van Grevenstein WMU; Verkooijen HM
    Eur J Surg Oncol; 2018 Jul; 44(7):1013-1017. PubMed ID: 29650419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study.
    Senyurek S; Saglam S; Saglam EK; Yanar H; Gok K; Tastekin D; Akbas CK; Sakin ND; Kartal GD; Balik E; Keskin M; Sanli Y; Gulluoglu M; Akgun Z
    Oncol Res; 2023; 31(5):689-696. PubMed ID: 37547762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External Validation of Early Regression Index (ERI
    Cusumano D; Boldrini L; Yadav P; Yu G; Musurunu B; Chiloiro G; Piras A; Lenkowicz J; Placidi L; Broggi S; Romano A; Mori M; Barbaro B; Azario L; Gambacorta MA; De Spirito M; Bassetti MF; Yang Y; Fiorino C; Valentini V
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1347-1356. PubMed ID: 32758641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
    Zhu J; Gu W; Lian P; Sheng W; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2013 May; 8():130. PubMed ID: 23718210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
    Ye W; Shi L; Qian L; Sun Y; Sun X
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
    Dellas K; Höhler T; Reese T; Würschmidt F; Engel E; Rödel C; Wagner W; Richter M; Arnold D; Dunst J
    Radiat Oncol; 2013 Apr; 8():90. PubMed ID: 23587311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delta radiomics for rectal cancer response prediction with hybrid 0.35 T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach.
    Boldrini L; Cusumano D; Chiloiro G; Casà C; Masciocchi C; Lenkowicz J; Cellini F; Dinapoli N; Azario L; Teodoli S; Gambacorta MA; De Spirito M; Valentini V
    Radiol Med; 2019 Feb; 124(2):145-153. PubMed ID: 30374650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.
    Valentini V; Coco C; Picciocchi A; Morganti AG; Trodella L; Ciabattoni A; Cellini F; Barbaro B; Cogliandolo S; Nuzzo G; Doglietto GB; Ambesi-Impiombato F; Cosimelli M
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):664-74. PubMed ID: 12062610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with Capecitabine in locally advanced rectal cancer: short-term results of a multicentric study.
    Lupattelli M; Matrone F; Gambacorta MA; Osti M; Macchia G; Palazzari E; Nicosia L; Navarria F; Chiloiro G; Valentini V; Aristei C; De Paoli A
    Radiat Oncol; 2017 Aug; 12(1):139. PubMed ID: 28830475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
    Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and Cadonilimab for locally advanced rectal cancer: a protocol of a phase II study.
    Xu T; Feng L; Zhang W; Li H; Ma H; Abulimiti M; Tan Y; Deng F; Huang W; Zou S; Kang W; Jiang L; Wang Y; Hu C; Chen Y; Zhou H; Tang Y; Jin J
    BMC Cancer; 2024 Apr; 24(1):501. PubMed ID: 38641773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
    Vestermark LW; Jensen HA; Pfeiffer P
    Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.